Target intelligence / Profile preview

DNA polymerase III subunit beta (DnaN) (DnaN)

Target
DnaN
Molecular classification
Enzyme, DNA-binding protein, Processivity factor, Protein scaffold
01

Overview

Pseudomonas aeruginosa DnaN, also known as the beta-clamp or DNA polymerase III subunit beta, is a critical component of the bacterial replisome. It functions as a ring-shaped processivity factor that encircles DNA, tethering the DNA polymerase III catalytic core to the template and allowing for rapid, continuous synthesis of the bacterial genome. Beyond its role in replication, DnaN serves as a central scaffold for various DNA repair enzymes and the clamp-loader complex. Its essential nature for bacterial viability and its significant structural divergence from the human equivalent, PCNA, make it a high-priority target for novel antimicrobial development. While no drugs are currently approved for clinical use against this specific Pseudomonas target, investigational compounds such as griselimycin and its derivatives have shown potent activity by binding to the hydrophobic pocket on the clamp surface, thereby halting DNA replication and causing bacterial cell death.

Other names
Beta-clampDNA sliding clampDNA polymerase III beta subunitSliding clamp proteinDnaN protein
02

Mechanism of action

Inhibits DNA replication by binding to the DnaN sliding clamp and competitively blocking its interaction with the replicative DNA polymerase (Pol III alpha subunit) and other repair/clamp-loader proteins at the C-terminal binding pocket.

03

Biological functions

DNA replicationDNA repairPolymerase processivityProtein-protein interaction hub
04

Disease associations

Infection
05

Safety considerations

Selective toxicity (distinguishing bacterial DnaN from human Proliferating Cell Nuclear Antigen/PCNA)Rapid development of resistance through gene duplication or amplificationGram-negative cell wall penetration for peptide-based inhibitors
06

Interacting drugs

Griselimycin

2 more in the full profile.

07

Biomarkers

Bacterial load (CFU)dnaN gene amplificationTarget site mutations (resistance markers)

Beyond the preview

Go deeper on DNA polymerase III subunit beta (DnaN) (DnaN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA polymerase III subunit beta (DnaN) (DnaN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call